The best way to end the pandemic? Early treatment!

99.76% risk reduction from hospitalization; 100% risk reduction from death. Plus they don’t cause death or disability (like the COVID vaccines do). This is why they are being suppressed by the NIH.


Early treatment is the true win-win: for you and for society

It’s the patriotic thing to do to end the pandemic.

We need to educate everyone on early treatment protocols. Look at the benefits:

  1. Treatments are super safe never kill or disable you
  2. You will avoid getting long-haul COVID
  3. Higher relative risk reduction than any vaccine or big-company pharma proprietary drug. For the Fareed-Tyson protocol, we have 99.76% reduction in hospitalization, and 100% reduction in death rate. There is nothing better that. Nothing.
  4. After you recover, if you catch COVID again, you won’t get sick or infect anyone else. None of these are true if you get vaccinated.
  5. After you recover, you can’t pass on the virus to anyone else (like you can if you just get vaccinated). This is important. This keeps others safe. It is the right thing to do for society. It is the patriotic thing to do.

What’s the catch? They only work if you take the drugs and are treated early (as soon as you have symptoms).

For more information on effective early treatments, see my article on early treatments.

The big problem was never the virus; it is our response to the virus

Meanwhile, the effectiveness of early treatments will continue to be suppressed by the CDC, FDA, NIH, AMA, and WHO among others.

COVID-19 early treatment: real-time analysis of 1,141 studies


Analysis of 30 COVID-19 early treatments, and database of 225 other potential treatments66 countries have approved early treatments. Treatments do not replace vaccines and other measures. All practical, effective, and safe means should be used. Elimination is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all variants. Denying efficacy increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage.

The Gateway Pundit – WONDER DRUG: New International Ivermectin Report of 64 Studies Shows 86% Success as Prophylaxis and 67% Success in Early Treatment

By Jim Hoft


PDF source for Ivermectin for COVID-19 real time meta analysis of 65 studies:

Covid studies for hydroxychloroquine :

A new international report of 64 studies shows Ivermectin has an 86% success rate as a prphylaxis and a 67% success rate in early treatment of coronavirus.

The results mirror the over 290 studies on hydroxychloroquine that have been reported over the past year.

The CDC, Dr. Fauci and the FDA ridiculed the use of the drugs to treat the China Virus despite their continued effectiveness in peer reviewed studies. At some point they are going to have to put their pride aside and admit they were wrong and the likely cause of millions of deaths from the deadly virus.

Study – Myocarditis – Early Biopsy Allows for Tailored Regenerative Treatment




Acute myocarditis mostly does not sufficiently respond to symptomatic medication for heart failure, and mortality is high in spite of treatment. The long-term disease course depends on the pathogen, the extent and type of inflammation, and the initial injury to the myocardium. Focal borderline myocarditis often undergoes spontaneous clinical healing if no serious heart failure developed initially. The early mortality of fulminant lymphocytic myocarditis requiring intensive care is in excess of 40% in the first 4 weeks (7). Untreated giant cell and eosinophilic myocarditis also have an extremely poor prognosis, with 4 year survival rates of less than 20% (8). Granulomatous necrotizing myocarditis is lethal if overlooked and untreated. Non-fulminant active myocarditis has a mortality rate of 25% to 56% within 3 to 10 years, owing to progressive heart failure and sudden cardiac death, especially if symptomatic heart failure manifests early on (9– 11e1). In addition to impaired left ventricular (LV) and right ventricular (RV) function, virus persistence, chronic inflammation, and cardiodepressive autoantibodies are independent predictors of a poor prognosis (91213).

Background and methods

Myocarditis and inflammatory cardiomyopathies can be caused by infections, drugs, toxic substances, and autoimmune diseases. We present their clinical features, diagnostic evaluation, treatment, and prognosis on the basis of a selective review of the literature, current expert opinion, and our own clinical experience.


The pathological mechanisms that are accessible to treatment lie at the cellular and molecular levels and generally give rise to nonspecific disease manifestations. Specific treatment is possible only on the basis of a standardized diagnostic evaluation of a biopsy specimen, rather than clinical examination alone. Therapeutic decisions must be based on the results of thorough myocardial biopsy studies while taking account of the individual patient’s clinical course. Moreover, treatment can help only if a treatable cause is present (e.g., a viral infection, an inflammatory process, or cardiodepressive antibodies), and only if the myocardium still has regenerative potential. Once irreversible myocardial injury has occurred—for example, if the diagnosis of post-infectious or post-inflammatory dilated cardiomyopathy has been missed until it is too late—then the development or progression of heart failure in the long term can no longer be prevented.


Recent studies have shown that specific treatment can help patients with viral, inflammatory, or autoimmune cardiomyopathy that has been precisely characterized by means of a myocardial biopsy. More randomized trials with larger patient cohorts are needed for further optimization of treatment.

The term myocarditis describes inflammatory disorders of the heart muscle of varied infectious and non-infectious origin (Box). In acute myocarditis, infectious strains usually cause myocardial inflammation with subsequent disturbance of left ventricular or right ventricular function. In Western industrialized countries these pathogens are primarily viruses, whereas in developing countries the cause may be bacterial, protozoal, or fungal infections. Myocardial processes triggered by infectious and non-infectious causes also underlie the chronic-inflammatory myocardial disorders (Figure 1). If the immune system does not eliminate the infectious pathogen early on—owing to insufficient activation, e.g. on the basis of a genetic predisposition—chronic infection develops, which may or may not be accompanied by inflammation (1). If the inflammatory response does not spontaneously resolve after successful elimination of the pathogen, chronic-inflammatory cardiomyopathy is present (Figure 1) (2). In addition to such postinfectious inflammatory processes, accompanying cellular or humoral inflammations in systemic diseases may cause lasting injury to the myocardium.

UFOTV® The Disclosure Network – Forbidden Archeology: SUPPRESSED New Evidence of Early Man – HD FEATURE


UFOTV® The Disclosure Network – Forbidden Archeology: SUPPRESSED New Evidence of Early Man – HD FEATURE

From the EMMY AWARD WINNING Producers of “The Mystery of the Sphinx” and the Producers of “The Mysterious Origins of Man” comes a new ground breaking film about “New Evidence of Early Man: SUPPRESSED.” What happens when scientific evidence conflicts with theory? In the early